A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/ UK Intercontinental Trial CRUKE/01/013).
Juanita Crook, Laurence Klotz(University of Toronto), Chris J. O’Callaghan(Unknown), Shawn Malone, Abdenour Nabid, J. Chin, Kevin Ding, Eliot Frymire, S. Larry Goldenberg(University of British Columbia), Tom Corbett, John Logue(San Antonio College), D.P. Dearnaley(Royal Marsden NHS Foundation Trust), E.M. Horwitz, Paul F. Schellhammer(Eastern Virginia Medical School), Fred Saad, Gillian Duncan(University of British Columbia), Steve Angyalfi, Celestia S. Higano(University of British Columbia), M.K. Gospodarowicz, Padraig Warde(University Health Network)
Cited by 51
Related Papers
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k